GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Total Payout Yield %

Alphamab Oncology (HKSE:09966) Total Payout Yield % : -10.84 (As of Jan. 18, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Alphamab Oncology's current Total Payout Yield % is -10.84%.


Alphamab Oncology Total Payout Yield % Historical Data

The historical data trend for Alphamab Oncology's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Total Payout Yield % Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Yield %
Get a 7-Day Free Trial -14.59 -1.93 - - -5.49

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - -9.98 0.28 -0.01

Competitive Comparison of Alphamab Oncology's Total Payout Yield %

For the Biotechnology subindustry, Alphamab Oncology's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphamab Oncology's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Total Payout Yield % falls into.



Alphamab Oncology Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Alphamab Oncology's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 351.14 + 0) / 6399.58552
=-5.49%

Alphamab Oncology's annualized Total Payout Yield % for the quarter that ended in Jun. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0.15 + 0) * 2 / 2313.5712
=-0.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alphamab Oncology Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Alphamab Oncology Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.
Executives
South Dakota Trust Company Llc 2301 Trustee
Xu Ting 2305 Beneficiary of a trust
Liu Yang 2307 Founder of a discretionary trust who can infl
Rubymab Ltd. 2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines